Loading…
Comparative effectiveness of dimethyl fumarate in multiple sclerosis
Aims To assess the effectiveness of dimethyl fumarate (DMF) on annual rate of relapse subject to treatment (ARRt) and disability progression in multiple sclerosis (MS) compared to injectable immunomodulators (IMM), teriflunomide (TERI) and fingolimob (FTY), in real‐life setting. Methods A population...
Saved in:
| Published in: | British journal of clinical pharmacology 2022-03, Vol.88 (3), p.1268-1278 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4601-86ca0f780aec9ddcfc50955536fef8ba6d9fbd6e085bf1f8c9090e99c9f457503 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4601-86ca0f780aec9ddcfc50955536fef8ba6d9fbd6e085bf1f8c9090e99c9f457503 |
| container_end_page | 1278 |
| container_issue | 3 |
| container_start_page | 1268 |
| container_title | British journal of clinical pharmacology |
| container_volume | 88 |
| creator | Bosco‐Lévy, Pauline Debouverie, Marc Brochet, Bruno Guillemin, Francis Louapre, Céline Maillart, Elisabeth Heinzlef, Olivier Lignot, Séverine Diez, Pauline Abouelfath, Abdelilah Lassalle, Régis Blin, Patrick Droz‐Perroteau, Cécile |
| description | Aims
To assess the effectiveness of dimethyl fumarate (DMF) on annual rate of relapse subject to treatment (ARRt) and disability progression in multiple sclerosis (MS) compared to injectable immunomodulators (IMM), teriflunomide (TERI) and fingolimob (FTY), in real‐life setting.
Methods
A population‐based cohort study was conducted using data of the French nationwide claims database, SNDS. All patients initiating IMM, TERI, FTY or DMF between 1 July 2015 and 12 December 2017, with 4.5 years of database history and 1–3.5 years of follow‐up were included in this study. DMF patients were 1:1 matched to IMM, TERI or FTY using a high dimensional propensity score. Negative binomial regression and a logistic regression model were used to estimate the relative risk (RR ± [95% CI]) of ARRt and the odds ratio (OR ± [95% CI]) of disability progression, respectively.
Results
Overall, 9304 subjects were identified: 29.0% initiated DMF, 33.2% TERI, 5.6% FTY and 32.2% an IMM. The matched cohorts consisted of 1779 DMF‐IMM patients, 1679 DMF‐TERI patients, and 376 DMF‐FTY patients. DMF significantly reduced ARRt compared to IMM (RR 0.72 [0.61–0.86]) and TERI (0.81 [0.68–0.96]) and did not show any significant difference when compared with FTY. The risk of the progression of MS‐specific disability was not significantly different for any matched cohorts.
Conclusion
DMF is associated with lower risk of treated relapse for patients with RRMS than other first‐line RRMS agents (TERI and IIM). |
| doi_str_mv | 10.1111/bcp.15071 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03622107v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2571921555</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4601-86ca0f780aec9ddcfc50955536fef8ba6d9fbd6e085bf1f8c9090e99c9f457503</originalsourceid><addsrcrecordid>eNp1kD1PwzAQhi0EoqUw8AdQRhjSnpPYicdSPopUCQaYLcc5q0ZOE-KmqP-ehJRueDnr9Oi5u5eQawpT2r1ZruspZZDSEzKmMWdhRCN2SsYQAw9ZxOiIXHj_CUBjytk5GcUJAxZDMiYPi6qsVaO2docBGoO6_23Q-6AyQWFL3K73LjBt2UMY2E1Qtm5ra4eB1w6bylt_Sc6Mch6vDnVCPp4e3xfLcPX6_LKYr0KdcKBhxrUCk2agUIui0EYzEIyxmBs0Wa54IUxecISM5YaaTAsQgEJoYRKWMogn5G7wrpWTdWO7nfayUlYu5yvZ9yDmUUQh3dGOvR3Yuqm-WvRbWVqv0Tm1war1MmIpFRHtxx-1urvGN2iObgqyD1h2AcvfgDv25qBt8xKLI_mXaAfMBuDbOtz_b5L3i7dB-QPtmYRV</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2571921555</pqid></control><display><type>article</type><title>Comparative effectiveness of dimethyl fumarate in multiple sclerosis</title><source>Wiley</source><creator>Bosco‐Lévy, Pauline ; Debouverie, Marc ; Brochet, Bruno ; Guillemin, Francis ; Louapre, Céline ; Maillart, Elisabeth ; Heinzlef, Olivier ; Lignot, Séverine ; Diez, Pauline ; Abouelfath, Abdelilah ; Lassalle, Régis ; Blin, Patrick ; Droz‐Perroteau, Cécile</creator><creatorcontrib>Bosco‐Lévy, Pauline ; Debouverie, Marc ; Brochet, Bruno ; Guillemin, Francis ; Louapre, Céline ; Maillart, Elisabeth ; Heinzlef, Olivier ; Lignot, Séverine ; Diez, Pauline ; Abouelfath, Abdelilah ; Lassalle, Régis ; Blin, Patrick ; Droz‐Perroteau, Cécile</creatorcontrib><description>Aims
To assess the effectiveness of dimethyl fumarate (DMF) on annual rate of relapse subject to treatment (ARRt) and disability progression in multiple sclerosis (MS) compared to injectable immunomodulators (IMM), teriflunomide (TERI) and fingolimob (FTY), in real‐life setting.
Methods
A population‐based cohort study was conducted using data of the French nationwide claims database, SNDS. All patients initiating IMM, TERI, FTY or DMF between 1 July 2015 and 12 December 2017, with 4.5 years of database history and 1–3.5 years of follow‐up were included in this study. DMF patients were 1:1 matched to IMM, TERI or FTY using a high dimensional propensity score. Negative binomial regression and a logistic regression model were used to estimate the relative risk (RR ± [95% CI]) of ARRt and the odds ratio (OR ± [95% CI]) of disability progression, respectively.
Results
Overall, 9304 subjects were identified: 29.0% initiated DMF, 33.2% TERI, 5.6% FTY and 32.2% an IMM. The matched cohorts consisted of 1779 DMF‐IMM patients, 1679 DMF‐TERI patients, and 376 DMF‐FTY patients. DMF significantly reduced ARRt compared to IMM (RR 0.72 [0.61–0.86]) and TERI (0.81 [0.68–0.96]) and did not show any significant difference when compared with FTY. The risk of the progression of MS‐specific disability was not significantly different for any matched cohorts.
Conclusion
DMF is associated with lower risk of treated relapse for patients with RRMS than other first‐line RRMS agents (TERI and IIM).</description><identifier>ISSN: 0306-5251</identifier><identifier>EISSN: 1365-2125</identifier><identifier>DOI: 10.1111/bcp.15071</identifier><identifier>PMID: 34505304</identifier><language>eng</language><publisher>England: Wiley</publisher><subject>cohort study ; dimethylfumarate ; effectiveness ; high dimensional propensity score ; Life Sciences ; multiple sclerosis ; Neurons and Cognition ; Pharmaceutical sciences ; Pharmacology ; relapse</subject><ispartof>British journal of clinical pharmacology, 2022-03, Vol.88 (3), p.1268-1278</ispartof><rights>2021 British Pharmacological Society</rights><rights>2021 British Pharmacological Society.</rights><rights>Attribution</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4601-86ca0f780aec9ddcfc50955536fef8ba6d9fbd6e085bf1f8c9090e99c9f457503</citedby><cites>FETCH-LOGICAL-c4601-86ca0f780aec9ddcfc50955536fef8ba6d9fbd6e085bf1f8c9090e99c9f457503</cites><orcidid>0000-0001-9763-5974 ; 0000-0003-3824-2796 ; 0000-0002-9860-7024</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbcp.15071$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbcp.15071$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,315,786,790,891,27957,27958,50923,51032</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34505304$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03622107$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Bosco‐Lévy, Pauline</creatorcontrib><creatorcontrib>Debouverie, Marc</creatorcontrib><creatorcontrib>Brochet, Bruno</creatorcontrib><creatorcontrib>Guillemin, Francis</creatorcontrib><creatorcontrib>Louapre, Céline</creatorcontrib><creatorcontrib>Maillart, Elisabeth</creatorcontrib><creatorcontrib>Heinzlef, Olivier</creatorcontrib><creatorcontrib>Lignot, Séverine</creatorcontrib><creatorcontrib>Diez, Pauline</creatorcontrib><creatorcontrib>Abouelfath, Abdelilah</creatorcontrib><creatorcontrib>Lassalle, Régis</creatorcontrib><creatorcontrib>Blin, Patrick</creatorcontrib><creatorcontrib>Droz‐Perroteau, Cécile</creatorcontrib><title>Comparative effectiveness of dimethyl fumarate in multiple sclerosis</title><title>British journal of clinical pharmacology</title><addtitle>Br J Clin Pharmacol</addtitle><description>Aims
To assess the effectiveness of dimethyl fumarate (DMF) on annual rate of relapse subject to treatment (ARRt) and disability progression in multiple sclerosis (MS) compared to injectable immunomodulators (IMM), teriflunomide (TERI) and fingolimob (FTY), in real‐life setting.
Methods
A population‐based cohort study was conducted using data of the French nationwide claims database, SNDS. All patients initiating IMM, TERI, FTY or DMF between 1 July 2015 and 12 December 2017, with 4.5 years of database history and 1–3.5 years of follow‐up were included in this study. DMF patients were 1:1 matched to IMM, TERI or FTY using a high dimensional propensity score. Negative binomial regression and a logistic regression model were used to estimate the relative risk (RR ± [95% CI]) of ARRt and the odds ratio (OR ± [95% CI]) of disability progression, respectively.
Results
Overall, 9304 subjects were identified: 29.0% initiated DMF, 33.2% TERI, 5.6% FTY and 32.2% an IMM. The matched cohorts consisted of 1779 DMF‐IMM patients, 1679 DMF‐TERI patients, and 376 DMF‐FTY patients. DMF significantly reduced ARRt compared to IMM (RR 0.72 [0.61–0.86]) and TERI (0.81 [0.68–0.96]) and did not show any significant difference when compared with FTY. The risk of the progression of MS‐specific disability was not significantly different for any matched cohorts.
Conclusion
DMF is associated with lower risk of treated relapse for patients with RRMS than other first‐line RRMS agents (TERI and IIM).</description><subject>cohort study</subject><subject>dimethylfumarate</subject><subject>effectiveness</subject><subject>high dimensional propensity score</subject><subject>Life Sciences</subject><subject>multiple sclerosis</subject><subject>Neurons and Cognition</subject><subject>Pharmaceutical sciences</subject><subject>Pharmacology</subject><subject>relapse</subject><issn>0306-5251</issn><issn>1365-2125</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kD1PwzAQhi0EoqUw8AdQRhjSnpPYicdSPopUCQaYLcc5q0ZOE-KmqP-ehJRueDnr9Oi5u5eQawpT2r1ZruspZZDSEzKmMWdhRCN2SsYQAw9ZxOiIXHj_CUBjytk5GcUJAxZDMiYPi6qsVaO2docBGoO6_23Q-6AyQWFL3K73LjBt2UMY2E1Qtm5ra4eB1w6bylt_Sc6Mch6vDnVCPp4e3xfLcPX6_LKYr0KdcKBhxrUCk2agUIui0EYzEIyxmBs0Wa54IUxecISM5YaaTAsQgEJoYRKWMogn5G7wrpWTdWO7nfayUlYu5yvZ9yDmUUQh3dGOvR3Yuqm-WvRbWVqv0Tm1war1MmIpFRHtxx-1urvGN2iObgqyD1h2AcvfgDv25qBt8xKLI_mXaAfMBuDbOtz_b5L3i7dB-QPtmYRV</recordid><startdate>202203</startdate><enddate>202203</enddate><creator>Bosco‐Lévy, Pauline</creator><creator>Debouverie, Marc</creator><creator>Brochet, Bruno</creator><creator>Guillemin, Francis</creator><creator>Louapre, Céline</creator><creator>Maillart, Elisabeth</creator><creator>Heinzlef, Olivier</creator><creator>Lignot, Séverine</creator><creator>Diez, Pauline</creator><creator>Abouelfath, Abdelilah</creator><creator>Lassalle, Régis</creator><creator>Blin, Patrick</creator><creator>Droz‐Perroteau, Cécile</creator><general>Wiley</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-9763-5974</orcidid><orcidid>https://orcid.org/0000-0003-3824-2796</orcidid><orcidid>https://orcid.org/0000-0002-9860-7024</orcidid></search><sort><creationdate>202203</creationdate><title>Comparative effectiveness of dimethyl fumarate in multiple sclerosis</title><author>Bosco‐Lévy, Pauline ; Debouverie, Marc ; Brochet, Bruno ; Guillemin, Francis ; Louapre, Céline ; Maillart, Elisabeth ; Heinzlef, Olivier ; Lignot, Séverine ; Diez, Pauline ; Abouelfath, Abdelilah ; Lassalle, Régis ; Blin, Patrick ; Droz‐Perroteau, Cécile</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4601-86ca0f780aec9ddcfc50955536fef8ba6d9fbd6e085bf1f8c9090e99c9f457503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>cohort study</topic><topic>dimethylfumarate</topic><topic>effectiveness</topic><topic>high dimensional propensity score</topic><topic>Life Sciences</topic><topic>multiple sclerosis</topic><topic>Neurons and Cognition</topic><topic>Pharmaceutical sciences</topic><topic>Pharmacology</topic><topic>relapse</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bosco‐Lévy, Pauline</creatorcontrib><creatorcontrib>Debouverie, Marc</creatorcontrib><creatorcontrib>Brochet, Bruno</creatorcontrib><creatorcontrib>Guillemin, Francis</creatorcontrib><creatorcontrib>Louapre, Céline</creatorcontrib><creatorcontrib>Maillart, Elisabeth</creatorcontrib><creatorcontrib>Heinzlef, Olivier</creatorcontrib><creatorcontrib>Lignot, Séverine</creatorcontrib><creatorcontrib>Diez, Pauline</creatorcontrib><creatorcontrib>Abouelfath, Abdelilah</creatorcontrib><creatorcontrib>Lassalle, Régis</creatorcontrib><creatorcontrib>Blin, Patrick</creatorcontrib><creatorcontrib>Droz‐Perroteau, Cécile</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>British journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bosco‐Lévy, Pauline</au><au>Debouverie, Marc</au><au>Brochet, Bruno</au><au>Guillemin, Francis</au><au>Louapre, Céline</au><au>Maillart, Elisabeth</au><au>Heinzlef, Olivier</au><au>Lignot, Séverine</au><au>Diez, Pauline</au><au>Abouelfath, Abdelilah</au><au>Lassalle, Régis</au><au>Blin, Patrick</au><au>Droz‐Perroteau, Cécile</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative effectiveness of dimethyl fumarate in multiple sclerosis</atitle><jtitle>British journal of clinical pharmacology</jtitle><addtitle>Br J Clin Pharmacol</addtitle><date>2022-03</date><risdate>2022</risdate><volume>88</volume><issue>3</issue><spage>1268</spage><epage>1278</epage><pages>1268-1278</pages><issn>0306-5251</issn><eissn>1365-2125</eissn><notes>Funding information</notes><notes>Biogen; University of Bordeaux</notes><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Aims
To assess the effectiveness of dimethyl fumarate (DMF) on annual rate of relapse subject to treatment (ARRt) and disability progression in multiple sclerosis (MS) compared to injectable immunomodulators (IMM), teriflunomide (TERI) and fingolimob (FTY), in real‐life setting.
Methods
A population‐based cohort study was conducted using data of the French nationwide claims database, SNDS. All patients initiating IMM, TERI, FTY or DMF between 1 July 2015 and 12 December 2017, with 4.5 years of database history and 1–3.5 years of follow‐up were included in this study. DMF patients were 1:1 matched to IMM, TERI or FTY using a high dimensional propensity score. Negative binomial regression and a logistic regression model were used to estimate the relative risk (RR ± [95% CI]) of ARRt and the odds ratio (OR ± [95% CI]) of disability progression, respectively.
Results
Overall, 9304 subjects were identified: 29.0% initiated DMF, 33.2% TERI, 5.6% FTY and 32.2% an IMM. The matched cohorts consisted of 1779 DMF‐IMM patients, 1679 DMF‐TERI patients, and 376 DMF‐FTY patients. DMF significantly reduced ARRt compared to IMM (RR 0.72 [0.61–0.86]) and TERI (0.81 [0.68–0.96]) and did not show any significant difference when compared with FTY. The risk of the progression of MS‐specific disability was not significantly different for any matched cohorts.
Conclusion
DMF is associated with lower risk of treated relapse for patients with RRMS than other first‐line RRMS agents (TERI and IIM).</abstract><cop>England</cop><pub>Wiley</pub><pmid>34505304</pmid><doi>10.1111/bcp.15071</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-9763-5974</orcidid><orcidid>https://orcid.org/0000-0003-3824-2796</orcidid><orcidid>https://orcid.org/0000-0002-9860-7024</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-5251 |
| ispartof | British journal of clinical pharmacology, 2022-03, Vol.88 (3), p.1268-1278 |
| issn | 0306-5251 1365-2125 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03622107v1 |
| source | Wiley |
| subjects | cohort study dimethylfumarate effectiveness high dimensional propensity score Life Sciences multiple sclerosis Neurons and Cognition Pharmaceutical sciences Pharmacology relapse |
| title | Comparative effectiveness of dimethyl fumarate in multiple sclerosis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T10%3A47%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20effectiveness%20of%20dimethyl%20fumarate%20in%20multiple%20sclerosis&rft.jtitle=British%20journal%20of%20clinical%20pharmacology&rft.au=Bosco%E2%80%90L%C3%A9vy,%20Pauline&rft.date=2022-03&rft.volume=88&rft.issue=3&rft.spage=1268&rft.epage=1278&rft.pages=1268-1278&rft.issn=0306-5251&rft.eissn=1365-2125&rft_id=info:doi/10.1111/bcp.15071&rft_dat=%3Cproquest_hal_p%3E2571921555%3C/proquest_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4601-86ca0f780aec9ddcfc50955536fef8ba6d9fbd6e085bf1f8c9090e99c9f457503%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2571921555&rft_id=info:pmid/34505304&rfr_iscdi=true |